APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF…

Lane

Equity financing

Announced

09 Jun 2026

Province

Ontario

Industry

Healthcare & life sciences

Status

Announced

What the filing says

Apotex Health Corp. (" Apotex " or the " Company ") today announced the pricing of its upsized initial public offering of 54,166,670 common shares of the Company (the " Common Shares ") at a price of $24.00 per Common Share (the " Offering Price "), for gross proceeds of $1,300,000,080 (the " Offering "), following the filing of the Company's final base PREP prospectus (the " Final Prospectus ") with the securities regulatory authorities in each of the provinces and territories of Canada, the issuance of a receipt for the Final Prospectus and the entering into of an underwriting agreement in…

Consideration

$1.30B

Credits

Goodmans LLP (legal advisor); Stikeman Elliott LLP (legal advisor); Kirkland & Ellis LLP (legal advisor); Skadden, Arps, Slate, Meagher & Flom LLP (legal advisor)

price per security

$22.00 (per Common Share)“Assuming an Offering size of approximately $1.3 billion and an Offering Price of $22.00 per Common Share (the midpoint of the Offering Price range), following completion of the Offering, an aggregate of 231,726,671 Common Shares will be issued and outstanding on a non-diluted basis (or 247,662,946 Common Shares on a fully diluted basis) and SK Artemis Holdings, II, LLC and API Investment LP will beneficially hold approximately 54.3% and 14.0% of the Common Shares (on a non-diluted basis), respectively (or 50.6% and 14.0% of the Common Shares (on a non-diluted basis) if the Over-Allotment Optio”

price per security

$24.00 (per Common Share)“APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING Apotex Health Corp. (" Apotex " or the " Company ") today announced the pricing of its upsized initial public offering of 54,166,670 common shares of the Company (the " Common Shares ") at a price of $24.00 per Common Share (the " Offering Price "), for gross proceeds of $1,300,000,080 (the " Offering "), following the filing of the Company's final base PREP prospectus (the " Final Prospectus ") with the securities regulatory authorities in each of the provinces and territories of Canada, the is”

Releases (3)

01 Jun 2026 — APOTEX HEALTH CORP. LAUNCHES ITS INITIAL PUBLIC OFFERING
08 Jun 2026 — APOTEX HEALTH CORP. UPSIZES ITS INITIAL PUBLIC OFFERING
09 Jun 2026 — APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

Source